We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+23.13%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$586M
AUM Growth
+$72M
Cap. Flow
+$10.1M
Cap. Flow %
1.72%
Top 10 Hldgs %
54.34%
Holding
53
New
16
Increased
10
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$29.5M
2
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$18.3M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$15.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.1M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.8M

Top Sells

Rank Stock Value
1
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$26.9M
2
RXDX
Ignyta, Inc.
RXDX
+$15.3M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$11.3M
4
RNAC icon
Cartesian Therapeutics
RNAC
+$10.5M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$9.49M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
1
DELISTED
Zogenix, Inc.
ZGNX
$44.9M 7.66%
1,121,331
+100,000
+10% +$3.84M
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
$40M 6.82%
1,177,119
-180,681
-13% -$5.15M
KURA icon
3
Kura Oncology
KURA
$800M
$33.6M 5.74%
2,197,283
+446,396
+25% +$6.58M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$32.9M 5.62%
200,000
+90,500
+83% +$8.77M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$31.6M 5.39%
803,205
+242,707
+43% +$9.06M
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$31M 5.3%
400,000
-75,000
-16% -$5.12M
RIGL icon
7
Rigel Pharmaceuticals
RIGL
$681M
$30.6M 5.22%
788,858
-121,711
-13% -$4.63M
FOMX
8
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$28.7M 4.9%
4,781,708
– –
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.28B
$23.3M 3.98%
4,751,883
+3,114,551
+190% +$15.1M
AIMT
10
DELISTED
Aimmune Therapeutics
AIMT
$21.7M 3.7%
573,550
+73,550
+15% +$2.37M
ONCE
11
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$21.1M 3.61%
+410,900
New +$29.5M
PTCT icon
12
PTC Therapeutics
PTCT
$5.68B
$18.1M 3.09%
1,085,800
-14,200
-1% -$240K
NVCR icon
13
NovoCure
NVCR
$1.73B
$17.8M 3.03%
879,286
+701,620
+395% +$13.5M
CNCE
14
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$17.3M 2.96%
669,472
-1,336,739
-67% -$26.9M
LUMO
15
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$16.1M 2.75%
+220,789
New +$18.3M
IOVA icon
16
Iovance Biotherapeutics
IOVA
$1.82B
$16M 2.73%
2,000,000
– –
SIOX
17
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$15M 2.56%
356,250
+355,040
+29,342% +$15.9M
CPRX
18
DELISTED
Catalyst Pharmaceutical
CPRX
$14.9M 2.55%
+3,817,288
New +$12.6M
BHVN
19
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$13.5M 2.3%
+500,192
New +$13.8M
SVRA icon
20
Savara
SVRA
$1.12B
$12.9M 2.2%
+869,500
New +$9.97M
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$307M
$12.1M 2.07%
797,531
+300,000
+60% +$4.45M
WVE icon
22
Wave Life Sciences
WVE
$1.09B
$11.6M 1.98%
+331,085
New +$9.65M
RVNC
23
DELISTED
Revance Therapeutics, Inc.
RVNC
$10.7M 1.83%
+300,000
New +$8.62M
GWPH
24
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.9M 1.69%
+75,000
New +$8.81M
GBT
25
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$7.87M 1.34%
+200,000
New +$7.47M
1
2 3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2017 Portfolio in Review

As of Q4 2017, Great Point Partners held 53 positions worth $586M, up 14% from $514M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Great Point Partners's Q4 2017 filing shows 16 new, 10 increased, 8 reduced and 14 closed positions. Its largest new stake was Spark Therapeutics, Inc. Common Stock: 410,900 shares worth $21.1M. The largest sale was Concert Pharmaceuticals, Inc., an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 69% a quarter earlier, followed by Technology.

  • Great Point Partners's largest Q4 2017 buy was Spark Therapeutics, Inc. Common Stock: 410,900 shares worth $21.1M.
  • Great Point Partners added most to Sio Gene Therapies Inc. Common Stock in Q4 2017, an estimated $15.9M increase.
  • Great Point Partners's biggest Q4 2017 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $26.9M.
  • Great Point Partners fully exited Ignyta, Inc. in Q4 2017, selling an estimated $15.3M.
  • Great Point Partners's ten largest holdings make up 54% of its $586M portfolio in Q4 2017.
  • Great Point Partners opened 16 new positions and closed 14 in Q4 2017.
  • Great Point Partners's portfolio value rose 14% quarter-over-quarter to $586M.

Based on Great Point Partners's 13F filing for Q4 2017, filed 14 Feb 2018.